Phase 3 PATINA trial results to FDA approval of Palbociclib (Ibrance) plus trastuzumab (Herceptin), with or without pertuzumab (Perjeta), and endocrine therapy for those with HER2 +, HR+ MBC
Read more here: buff.ly/8H64evz
#BreastCancerResearch #FDAApproval #BCSM #CanSky